Candel Therapeutics, Inc. (CADL)
After hours:
| Previous close | 6.43 |
| Open | 6.59 |
| Bid | 6.35 x 400 |
| Ask | 6.43 x 400 |
| Day's range | 6.02 - 6.60 |
| 52-week range | 0.66 - 11.40 |
| Volume | |
| Avg. volume | 5,298,636 |
| Market cap | 187.531M |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.31 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.00 |
GlobeNewswireCandel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4, 2024, in Chicago, IL. The first presentation will feature data from the ongoing
ZacksCandel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
- GlobeNewswire
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer. “We recently reported dat
